Targeted Therapy and Imaging Findings

Area of Science:

• Oncology
• Medical Imaging
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is often diagnosed at advanced stages, limiting curative surgical or radiation options.
• Current median survival for advanced NSCLC is approximately 10 months, highlighting the need for improved systemic therapies.
• Treatment paradigms are evolving towards personalized medicine, driven by the identification of specific genetic biomarkers.

Purpose of the Study:

• To discuss the imaging characteristics of advanced NSCLC with identified genetic abnormalities.
• To review the evolution of targeted therapies for NSCLC based on genetic mutations.
• To describe the imaging manifestations of these targeted therapies.

Main Methods:

• Review of current literature on NSCLC genetics, targeted therapies, and imaging.
• Analysis of imaging findings in patients with EGFR and ALK mutations.
• Correlation of therapeutic interventions with imaging response.

Main Results:

• Genetic mutations such as EGFR and ALK drive tumor growth in NSCLC.
• Targeted therapies (e.g., erlotinib, gefitinib, crizotinib) are effective against specific mutations.
• Antiangiogenesis agents like bevacizumab offer another therapeutic avenue.
• Distinct imaging patterns are associated with specific genetic profiles and treatment responses.

Conclusions:

• Personalized treatment strategies based on genetic biomarkers are crucial for advanced NSCLC.
• Targeted therapies demonstrate efficacy in NSCLC harboring specific mutations.
• Imaging plays a vital role in characterizing NSCLC, monitoring treatment response, and understanding therapeutic effects.